Recent Updates — TEVJF

On September 9, 2026, Teva Pharmaceutical Finance Netherlands II B.V., III B.V., and IV B.V. entered into an underwriting agreement to sell approximately $4.9 billion in aggregate principal amount of senior notes, with Teva acting as guarantor. The offering includes €1.5 billion in Euro-denominated notes maturing in 2033 (4.250%) and 2036 (4.625%), and $3.2 billion in USD-denominated notes maturing in 2032 (5.250%), 2034 (5.500%), and 2037 (5.750%). Settlement is expected on September 16, 2026. Teva intends to use the net proceeds to fund conditional redemptions of existing notes, including all outstanding 6.750% Senior Notes due 2028, 7.875% and 7.375% Sustainability-Linked Senior Notes due 2029, up to $450 million in 4.750% notes due 2027, and up to €1.15 billion in 4.375% notes due 2030. Teva Pharmaceutical Industries Limited is a global leader in the generic pharmaceuticals industry.